CART targeting of solid tumors: more pieces to the puzzle
M Kalos - Clinical Cancer Research, 2018 - AACR
M Kalos
Clinical Cancer Research, 2018•AACRChimeric antigen receptor–modified T (CART)-cell–based targeting of solid tumors remains
a considerable and worthwhile challenge in the field of immunotherapy. The role of
chemotherapy to target stroma and enhance chimeric antigen receptor (CAR) cell antitumor
function, expansion, and persistence is still unresolved. Clin Cancer Res; 24 (6); 1246–7.©
2018 AACR. See related article by Guo et al., p. 1277
a considerable and worthwhile challenge in the field of immunotherapy. The role of
chemotherapy to target stroma and enhance chimeric antigen receptor (CAR) cell antitumor
function, expansion, and persistence is still unresolved. Clin Cancer Res; 24 (6); 1246–7.©
2018 AACR. See related article by Guo et al., p. 1277
Abstract
Chimeric antigen receptor–modified T (CART)-cell–based targeting of solid tumors remains a considerable and worthwhile challenge in the field of immunotherapy. The role of chemotherapy to target stroma and enhance chimeric antigen receptor (CAR) cell antitumor function, expansion, and persistence is still unresolved. Clin Cancer Res; 24(6); 1246–7. ©2018 AACR.
See related article by Guo et al., p. 1277
AACR
